Loading KVUE detail
Loading ticker data...
Loading KVUE detail
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health.
The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
Chart data unavailable
Alpha Omega Wealth Management LLC decreased its position in Kenvue Inc. (NYSE: KVUE) by 53.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 142,619 shares of the company's stock after selling 167,069 shares during the quarter. Alpha Omega Wealth Management
Capricorn Fund Managers Ltd bought a new position in Kenvue Inc. (NYSE: KVUE) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 282,485 shares of the company's stock, valued at approximately $4,873,000. A number of other hedge funds
Tokyo Lifestyle (NASDAQ: TKLF - Get Free Report) and Kenvue (NYSE: KVUE - Get Free Report) are both consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Dividends Tokyo Lifestyle pays an annual dividend of
Kenvue (KVUE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Synergy CHC (NASDAQ: SNYR - Get Free Report) and Kenvue (NYSE: KVUE - Get Free Report) are both consumer staples companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation. Institutional and Insider Ownership 97.6% of Kenvue shares
Shares of Kenvue Inc. (NYSE: KVUE - Get Free Report) have been assigned a consensus recommendation of "Hold" from the sixteen brokerages that are currently covering the firm, MarketBeat.com reports. Thirteen analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among
Stocks are higher this afternoon, as investors brush off the latest U.S.-Iran war developments
Medtronic and Kimberly-Clark are Dividend Aristocrats trading well below historical valuations, offering compelling buy-the-dip opportunities. MDT has strong revenue growth, a robust innovation pipeline, and a 3.3% yield, with a forward P/E of 15.4 versus its historical 17.5. KMB is executing on transformation and innovation, with margin gains, a 5.2% yield, and a forward P/E of 13.0, far below its historical 17.7.
Kimberly-Clark Corporation is undergoing major transformation with a JV in Brazil and the $49B Kenvue acquisition. KMB's shift toward premium brands via KVUE increases revenue scale but introduces integration and brand loyalty risks amid consumer trade-down trends. Post-acquisition, leverage will rise to ~2.8x net debt/EBITDA, pausing share buybacks and potentially impacting credit ratings and dividend stability if synergies disappoint.
First Trust Advisors LP raised its stake in shares of Kenvue Inc. (NYSE: KVUE) by 200.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,667,217 shares of the company's stock after buying an additional 1,778,475 shares
CI Investments Inc. decreased its holdings in shares of Kenvue Inc. (NYSE: KVUE) by 98.2% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,485 shares of the company's stock after selling 519,412 shares during the period. CI
Barington Companies Management LLC acquired a new position in shares of Kenvue Inc. (NYSE: KVUE) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 50,000 shares of the company's stock, valued at approximately $812,000. Kenvue makes up about
Tylenol use among pregnant women fell after U.S. President Donald Trump linked autism to the over-the-counter pain relief medicine, according to an analysis of U.S. emergency room prescribing patterns published in the UK medical journal Lancet.
Investors looking for stocks in the Consumer Products - Staples sector might want to consider either Kenvue (KVUE) or Procter & Gamble (PG). But which of these two stocks offers value investors a better bang for their buck right now?
Bahl and Gaynor Inc. trimmed its position in Kenvue Inc. (NYSE: KVUE) by 35.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 108,824 shares of the company's stock after selling 58,886 shares during the quarter. Bahl and Gaynor Inc.'s holdings in
